BioMark Diagnostics Receives Clearance From Health Canada to Commence Clinical Trial With Patented Non-Invasive, Urine-Based Assay to Measure Response to Treatment for Lung Cancer

VANCOUVER, British Columbia, Sept. 9, 2015, OTCQB, BMKDF, CSE, BUX, (GLOBE NEWSWIRE) BioMark Diagnostics Inc. ( BioMark ) (CSE:BUX) (FSE:20B) (OTCQB:BMKDF) announces receipt of a No Objection Letter from Health Canada, clearing the way for a clinical trial with the company s metabolite-based assay using a urine sample to measure response to treatment for lung cancer. The trial will specifically look at lung cancer and response to treatment while the company continues its ongoing Phase III trial for BioMark s early stage, low cost general screening test which currently has 200 samples preparing to be analyzed. The trial will recruit patients with lung cancer who are being treated with chemotherapeutics with enrollment expected to begin during the fourth quarter of 2015.  Dr. Andrew Maksymiuk, Medical Oncologist at CancerCare Manitoba and Professor in the Faculty of Medicine at the University of Manitoba, will be the principal investigator. In 2014, Dr. Maksymiuk was awarded the Joan


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: